Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026)
Ardelyx's (ARDX) quarterly Total Non-Current Liabilities came in at $330.0 million in Q1 2026, up 38.67% YoY from $238.0 million in Q1 2025, and up 6.88% on a QoQ basis from $308.8 million in Q4 2025.
Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Total Non-Current Liabilities data on file, last reported at $330.0 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 38.67% year-over-year to $330.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330.0 million (up 38.67% YoY) and the FY2025 annual result came in at $308.8 million, up 30.32% from the prior year.
- Total Non-Current Liabilities grew to $330.0 million in Q1 2026, from $308.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $330.0 million in Q1 2026 to a low of $67.4 million in Q3 2022.
- A 5-year average of $176.5 million and a median of $171.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities grew 8.52% — and 2024, when it surged 131.65%.
- Tracing ARDX's Total Non-Current Liabilities over 5 years: stood at $80.5 million in 2022, then jumped by 37.4% to $110.6 million in 2023, then soared by 114.26% to $236.9 million in 2024, then soared by 30.32% to $308.8 million in 2025, then climbed by 6.88% to $330.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $330.0 million (Q1 2026), $308.8 million (Q4 2025), and $303.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 400.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400.56 Mn |
| Mar 31, 2026 | 330.02 Mn |
| Dec 31, 2025 | 308.78 Mn |
| Sep 30, 2025 | 303.26 Mn |
| Jun 30, 2025 | 299.48 Mn |
| Mar 31, 2025 | 238.00 Mn |
| Dec 31, 2024 | 236.94 Mn |
| Sep 30, 2024 | 185.19 Mn |
| Jun 30, 2024 | 173.39 Mn |
| Mar 31, 2024 | 169.61 Mn |
| Dec 31, 2023 | 110.58 Mn |
| Sep 30, 2023 | 98.05 Mn |
| Jun 30, 2023 | 74.85 Mn |
| Mar 31, 2023 | 79.38 Mn |
| Dec 31, 2022 | 80.48 Mn |
| Sep 30, 2022 | 67.39 Mn |
| Jun 30, 2022 | 68.98 Mn |
| Dec 31, 2021 | 67.30 Mn |
| Dec 31, 2020 | 74.07 Mn |
| Sep 30, 2020 | 65.96 Mn |